Étiquette : Ketamine

Repeated Ketamine Infusions Linked to Rapid Relief of PTSD, Deborah Brauser, Medscape.com, 2021

Repeated Ketamine Infusions Linked to Rapid Relief of PTSD Deborah Brauser Medscape. com, January 18, 2021 Medscape Medical News © 2021 www.medscape.com/viewarticle/944282_print   Repeated intravenous infusions of ketamine provide rapid relief for patients with posttraumatic stress disorder (PTSD), new research suggests. In what investigators are calling the first randomized controlled trial of repeated ketamine administration for chronic PTSD, 30 patients received six infusions of ketamine or midazolam (used as a psychoactive placebo) over 2 consecutive weeks. Between baseline and week 2, those receiving ketamine showed significantly greater improvement than those receiving midazolam. Total scores on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) for the first group were almost 12 points [...]

Lire la suite

Reviewing the Potential of Psychedelics for the Treatment of PTSD, Erwin Krediet et al., 2020

Reviewing the Potential of Psychedelics for the Treatment of PTSD Erwin Krediet, Tijmen Bostoen, Joost Breeksema, Annette van Schagen, Torsten Passie, Eric Vermetten International Journal of Neuropsychopharmacology, 2020, 23, (6), 385–400 doi : 10.1093/ijnp/pyaa018 https://pubmed.ncbi.nlm.nih.gov/32170326/   Abstract There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs with new mechanisms of action has stalled. Therefore, there is an urgent need to explore not [...]

Lire la suite

Development of Ketamine Administration as a Treatment for Chronic PTSD, Abigail B. Collins et al., 2020

Development of Ketamine Administration as a Treatment for Chronic PTSD Abigail B. Collins, BS; Sarah B. Rutter, MA; and Adriana Feder, MD Psychiatric Annals, 2020, 50, (2), 68-76. doi : 10.3928/00485713-20200109-01   ABSTRACT Posttraumatic stress disorder (PTSD) is a highly prevalent, chronic, and dis-abling condition for which currently available pharmacotherapies are insuf-ficiently effective. Ketamine, which is a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist, has emerged as a promising and rapid-act-ing novel treatment intervention for this disorder. Findings from a proof-of-concept, randomized, controlled cross-over study of single-dose intravenous ketamine administration (compared to single-dose midazolam) in patients with chronic PTSD suggest that ketamine is associated with rapid improvement in [...]

Lire la suite

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. A Randomized Clinical Trial, Alan K. Davis et al., 2020

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. A Randomized Clinical Trial Alan K. Davis, PhD; Frederick S. Barrett, PhD; Darrick G. May, MD; Mary P. Cosimano, MSW; Nathan D. Sepeda, BS; Matthew W. Johnson, PhD; Patrick H. Finan, PhD; Roland R. Griffiths, PhD JAMA Psychiatry, 2020, E1-E9. doi : 10.1001/jamapsychiatry.2020.3285   IMPORTANCE : Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects in patients with cancer and in those with treatment-resistant depression. OBJECTIVE : To investigate the effect of psilocybin [...]

Lire la suite

FDA Okays New Indication for Esketamine Nasal Spray, Megan Brooks, Medscape – Aug 03, 2020.

FDA Okays New Indication for Esketamine Nasal Spray Megan Brooks Medscape - Aug 03, 2020. The US Food and Drug Administration (FDA) has approved the supplemental new drug application for esketamine nasal spray (Spravato, Janssen Pharmaceuticals) to treat depressive symptoms in adults with major depressive disorder (MDD) and acute suicidal ideation or behavior. The FDA approved esketamine nasal spray for treatment-resistant depression in March 2019, as reported by Medscape Medical News. The new indication is based on data from two identical phase 3 trials — ASPIRE I and ASPIRE II — which evaluated the efficacy and safety of the nasal spray in addition to a comprehensive standard of care [...]

Lire la suite

Report et nouvelle date pour les 25ES Rencontres du RESPADD : Des drogues en santé mentale, 18 novembre 2020

Report et nouvelle date pour les 25ES Rencontres du RESPADD : Des drogues en santé mentale Affiche – 25es Rencontres RESPADD En raison de la situation sanitaire actuelle et pour préserver la santé de chacun, le RESPADD a décidé de reporter ses 25es Rencontres. NOUVELLE DATE : le 18 novembre 2020 Les 25es Rencontres professionnelles du RESPADD, réalisées en partenariat avec le Groupement addictions Franche-Comté, la Société psychédélique française et le CHS Saint-Ylie Jura, se tiendront le mercredi 18 novembre 2020 à la Commanderie de Dole. Cette nouvelle édition des Rencontres du RESPADD explorera les nouveaux usages des drogues en santé mentale et [...]

Lire la suite

The Reemergence of Ketamine for Treatment in Critically Ill Adults, Kimberly P. Hurth et al., 2020

The Reemergence of Ketamine for Treatment in Critically Ill Adults Kimberly P. Hurth,  Kristen B. Thomas,  Michael A. Rudoni Critical Care Medicine, 2020,1-13. Doi : 10.1097/CCM.0000000000004335   Objectives : To assess the evidence and discuss the risks and clinical relevance of ketamine for the treatment of various disease states impacting the adult critically ill population. Data Sources : A literature review was performed using PubMed evaluating primary literature published until August 2018. Study Selection : Case reports, observational studies (cohort, case-control), and randomized controlled trials involving patients 18 years and older in a nonperioperative setting using either IV or intramuscular ketamine were included for analysis. Uses of [...]

Lire la suite

Astrocytes in rapid ketamine antidepressant action, Matjaž Stenovec et al., 2020

Astrocytes in rapid ketamine antidepressant action Matjaž Stenovec, Baoman Li, Alexei Verkhratsky, Robert Zorec Neuropharmacology, 2020, 173, 108158 Doi : 10.1016/j.neuropharm.2020.108158   H I G H L I G H T S • Ketamine inhibits calcium signalling and enhances cAMP production in astroglia. • Ketamine suppresses exocytosis of gliosignalling molecules and Kir4.1. • Ketamine elevates cholesterol content in the plasmalemma specifically in astrocytes. A B S T R A C T Ketamine, a general anaesthetic and psychotomimetic drug, exerts rapid, potent and long-lasting antidepressant effect, albeit the cellular and molecular mechanisms of this action are yet to be discovered. Besides targeting neuronal NMDARs fundamental for synaptic transmission, ketamine affects the [...]

Lire la suite

Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition, Bernhard Luscher et al., 2020

Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition Bernhard Luscher, Mengyang Fenga, Sarah J. Jefferson Advances in Pharmacology, 2020 doi : 10.1016/bs.apha.2020.03.002   Contents 1. Introduction 3 2. Molecular targets of subanesthetic ketamine and its metabolites 6 3. Insights from ketamine indicate a key role for reduced GABAergic inhibition in the pathophysiology of major depression 7 3.1 Antidepressant efficacy of ketamine is controlled by imbalances between neural excitation and inhibition 7 3.2 Chronic imbalances of neural excitation and inhibition lead to homeostatic downregulation of glutamatergic synapses that compromises normal neuronal communication 9 3.3 Chronic imbalances between neural excitation and inhibition lead to defects in GABAergic inhibition that delimit spontaneous recovery from [...]

Lire la suite

Les effets antidépresseurs de la kétamine élucidés, Florence Rosier, Le Monde, 16 avril 2019

Les effets antidépresseurs de la kétamine élucidés Utilisée de longue date comme anesthésique, cette molécule vient d’être autorisée comme antidépresseur aux Etats-Unis. Par Florence Rosier Publié le 16 avril 2019 à 06h00 - https://www.lemonde.fr/sciences/article/2019/04/16/les-effets-antidepresseurs-de-la-ketamine-elucides_5450737_1650684.html   La kétamine est une molécule à surprises. Et pas seulement pour ceux qui recherchent ses effets hallucinogènes en la détournant de ses applications médicales. Depuis les années 1970, elle est largement utilisée comme anesthésique à usage humain ou vétérinaire. Mais elle est aussi dotée de puissants effets antidépresseurs, découverts voici plus de vingt ans. Or, ceux-ci viennent d’être doublement reconnus : au plan réglementaire, par la toute-puissante agence américaine du médicament (FDA) ; [...]

Lire la suite